With breast cancer affecting 1 in 8 women globally and approximately 2.3 million new cases each year, the need for advanced, patient-centered reconstruction options has never been more pressing. Traditional methods, often involving complex surgeries or multiple procedures, can pose significant recovery challenges. 4Tissue’s hydrogel technology addresses these issues by supporting natural tissue regeneration, providing durable and predictable results without the complications associated with implants or grafting.

This breakthrough is driven by a team of esteemed experts, including Prof. Phillip Blondeel, a world authority in plastic and reconstructive surgery and Prof. Sandra Van Vlierberghe, an internationally renowned expert in biomaterials. Their expertise, along with a highly skilled interdisciplinary team including Benoit Moreaux as CEO, An Van Den Bulcke as COO and Lana Van Damme as CSO, positions 4Tissue to navigate the full journey from innovation to clinical validation and commercialization.

The funding round, led by three prominent female investors—Annemie Van de Casteele, Griet Nuytinck, and Virginie Saverys—highlights 4Tissue’s potential to reshape the future of breast reconstruction. With additional governmental and European grants, 4Tissue is set to advance its mission of improving patient outcomes through regenerative medicine.